07:37 AM EDT, 07/14/2025 (MT Newswires) -- Astrazeneca ( AZN ) said Monday that a phase 3 study of Baxdrostat in patients with uncontrolled or treatment-resistant hypertension met its primary and all secondary endpoints.

Baxdrostat at two different dose levels showed a "statistically significant and clinically meaningful" reduction in mean seated systolic blood pressure, compared with placebo at 12 weeks, the company said.

The treatment was generally "well tolerated with a favorable" safety profile, Astrazeneca ( AZN ) said.

The data will be presented at a medical meeting in August, according to the company.